NCT Number: NCT02864017
Immuno Nutrition by L-citrulline for Critically Ill Patients
The main objective of this study is to demonstrate that the only administration of L-citrulline, can improve immune functions in critically ill patients at high risk of nosocomial infection.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
CHU Angers, Angers, France
About this study
This is a multicentric therapeutic trial, randomized and double blind: standard enteral nutrition plus L-citrulline (5 grams/12 Hours for 5 days from the admission in Intensive Care Unit (ICU)) versus standard enteral nutrition plus placebo.
Methods-Patients: Non-surgical patients admitted in medical intensive care unit, under mechanical ventilation for an expected duration > 2 days, without severe sepsis or septic shock, will be enrolled. Symptoms leading for ICU admission ongoing for five days maximum. On admission (before treatment), the severity will be evaluated with the Sepsis-related Organ Failure Assessment (SOFA) score together with an assessment of plasmatic arginine, cytokines (InterLeukin-6 (IL6) ), and expression of Human Leukocyte Antigen - antigen D Related (HLA-DR) by monocytes. The same evaluation will be repeated on day 3 (during treatment) and on day 7 (after treatment).
The enrolment of 100 patients is statistically enough to demonstrate a decreased SOFA scores in the L-citrulline group as compared to the placebo group on day 7.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- age > 18 years
- medical patient (absence of recent surgery or trauma)
- initial aggression < 5 days
- mechanically ventilated with expected duration of mechanical ventilation > 2 days
- exclusive enteral nutrition
- absence of previous immunosuppression
Exclusion criteria
- severe sepsis
- septic shock
- obesity defined as BMI above 40
- pregnancy
Treatment and study plan
L-citrulline
Dietary SupplementPlacebo
Dietary SupplementPrimary outcomes
-
Organ failure score comparison D7
Time frame: At day 7
Organ failure score (SOFA score) on day 7 in the L-citrulline group as compared to the placebo group
Secondary outcomes
-
Organ failure score comparison D3
Time frame: At day 3
Organ failure score (SOFA score) on day 3 in the L-citrulline group as compared to the placebo group
-
SOFA score evolution between randomisation and D7
Time frame: up to 7 days
Binary criterion of success or failure :
- Success is defined by: an improved SOFA score of at least 2 points from randomization to Day 7 or an improvement in the general condition yielding the release of the unit;
- Failure is defined by an improved SOFA score but less than 2 points, no improvement or worsening of the SOFA score from randomization to Day 7 or the patient's death before J7;
-
Expression of HLA-DR
Time frame: At day 7
Expression of HLA-DR in the L-citrulline group as compared to the placebo group
-
Plasmatic concentration of IL6
Time frame: At day 7
Comparison of the plasmatic concentration of interleukin-6 between the L-citrulline group and the placebo group
-
HLA-DR
Time frame: At day 7
Comparison of the percentage of expression of monocytic HLA-DR between the L-citrulline group and the placebo group
-
Plasmatic concentration of L-arginine
Time frame: At day 7
Comparison of the plasmatic concentration of L-arginine and its metabolites between the L-citrulline group and the placebo group
-
Incidence of nosocomial infections
Time frame: during the stay in the ICU, an average of 7 days
Comparison between the L-citrulline group and the placebo group
-
Length of stay
Time frame: during the stay in hospital, up to 28 days
Length of stay in ICU and hospital: Comparison between the L-citrulline group and the placebo group
-
Mortality
Time frame: during the stay in hospital, up to 28 days
- Mortality in intensive care and in hospital : Comparison between the L-citrulline group and the placebo group
- Duration of mechanical ventilation.
-
Duration of mechanical ventilation
Time frame: during the stay in ICU, an average of 7 days
Duration of mechanical ventilation: Comparison between the L-citrulline group and the placebo group
Sponsors and collaborators
Lead sponsor
Rennes University Hospital
Other
Registry information
Acronym: Immunocitre
Important dates
- Study start
- 2016
- Primary completion
- 2019
- Study completion
- 2020
- First posted
- Aug 11, 2016
- Registry last updated
- Jun 9, 2020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Low-dose Propofol Plus High-dose Alfentanil in Rapid Sequence Induction
NCT07730918
Hemodynamic Instability During Anesthesia, Induction Anesthesia
Zhangjiagang, Jiangsu, China
View Trial DetailsOpioid-free Analgesia in Intensive Care Unit
NCT05825560
Intubation
Nîmes, Gard, France
View Trial DetailsEffect of a Personalized Weaning Strategy on Weaning Success
NCT05719194
Intubation, Mechanical Ventilation
Bordeaux, France
View Trial DetailsThe Effect of an Suction Toothbrush on the Development of Ventilator-Associated Pneumonia
NCT07125495
Infection, Infections
Istanbul, Turkey (Türkiye)
View Trial Details